Literature DB >> 11149035

Albumin gradient and portal vein velocity in severe viral hepatitis patients complicated with ascites.

K W Chiu1, C S Changchien, Y F Liaw, S S Yang.   

Abstract

BACKGROUND/AIMS: To ascertain the mechanism of development of ascites and the hemodynamic change of portal system, 28 patients who had an episode of severe viral hepatitis with and without spontaneous bacterial peritonitis were studied.
METHODOLOGY: By means of a non-invasive duplex system, the relationships between the albumin gradient of serum-ascites and the portal vein velocity were assessed in 10 patients with spontaneous bacterial peritonitis and 18 patients without spontaneous bacterial peritonitis.
RESULTS: In the group of patients with severe form of hepatitis but without spontaneous bacterial peritonitis, there is a significant positive linear correlation between the level of serum albumin and the albumin gradient of serum-ascites (P < 0.001). However, a receded linear correlation was found between the serum albumin and the portal vein velocity (P < 0.02), and between the albumin gradient of serum-ascites and the portal vein velocity (P < 0.027) with Spearman linear correlation analysis.
CONCLUSIONS: The present study suggests that hypoalbuminemia may be related to impairment of synthesis function in severe hepatitis itself, but not to the intraabdominal shifting of protein. Decreased portal vein velocity may be the first presenting sign in patients with severe form hepatitis complicating simple ascites. Yet this relationship will be masked and complicated once spontaneous bacterial peritonitis occurs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149035

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  Percentage of peak-to-peak pulsatility of portal blood flow can predict right-sided congestive heart failure.

Authors:  Jui-Ting Hu; Sien-Sing Yang; Yun-Chih Lai; Cheng-Yen Shih; Cheng-Wen Chang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.